Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Prior to joining Alembic, he was working with Lupin Limited for more than 11 years
Currently, Venkat is Lead – Market Access, India at Pfizer
Almost 300 million people globally have chronic hepatitis B
Both the India and GCC entities will be operated by separate dedicated management teams
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Evinova will operate as a separate health-tech business within AstraZeneca
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Subscribe To Our Newsletter & Stay Updated
